Medicinal Chemistry Support Program for Therapeutic Development
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH), specifically the National Institute on Neurological Disorders and Stroke (NINDS) and the NIH Blueprint Neurotherapeutics Network (BPN), intends to issue a sole source modification to CURIA GLOBAL, INC. for the "Medicinal Chemistry Support Program for Therapeutic Development" (Contract No. HHSN271201800001I). This modification will increase the Single Award Indefinite Delivery, Indefinite Quantity (IDIQ) contract's maximum value by $30,145,159, raising it from $39,500,000 to $69,645,159. The purpose is to ensure the continuation of critical therapeutic development work and prevent disruption of support services for scientific research essential for ongoing and upcoming pre-clinical and clinical trials. Responses from interested parties are due by June 4, 2026, at 1:00 p.m. EDT.
Scope of Work
The existing contract provides comprehensive medicinal chemistry services, including SAR analysis and design, synthesis, in vitro ADMET, computational chemistry (CADD), and compound logistics. The program supports the development of small molecule, peptide, and biologic therapeutics within the NIH community, particularly for neurotherapeutics. The contract includes two performance areas:
- Performance Area 1: Tech Transfer, Storage Handling and Distribution, Access Training and IT Security Relevant to Existing Compound Repository, covering overall administration, project management, and technical support.
- Performance Area 2: Medicinal Chemistry Support, encompassing project planning, management, design and synthesis of chemical analogs, multi-gram and scale-up synthesis, in vitro ADME/toxicology testing, compound registration, and communication.
Contract & Timeline
- Type: Sole Source Modification to a Single Award IDIQ
- Contract No.: HHSN271201800001I
- Contractor: CURIA GLOBAL, INC.
- Modification Value: Increase of $30,145,159 (new maximum: $69,645,159)
- Ordering Period: March 16, 2018 to March 15, 2028 (unchanged)
- NAICS Code: 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)) with a 1,000-employee size standard.
- Statutory Authority: 41 U.S.C. 3304(a)(1) and FAR 6.103-1 (Only one responsible source).
- Response Due: June 4, 2026, 1:00 p.m. EDT
- Published: May 20, 2026
Action Items
This is not a request for competitive proposals. However, interested parties may submit capability statements or objections to the proposed sole source modification. Responses will be considered to determine if a competitive procurement is feasible. Potential offerors must have an active SAM registration, and include their UEI, TIN, and business size in their response. Submit responses electronically to Shaun Rostad at shaun.rostad@nih.gov.